68Ga-DOTATATE PET Scan in Neuroendocrine Cancer

Completed · Phase 2

Conditions studied: Neuroendocrine Carcinoma

In brief

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET scan is a new generation of scans that might have improved sensitivity and resolution specifically for neuroendocrine tumors. The investigators will scan people with this cancer and compare it to other conventional imaging methods to see if it improves patient care.

Key facts

Study ID
NCT01396382
Run by
Vanderbilt-Ingram Cancer Center
People needed
97
Starts
2010-03-01
Expected to finish
2014-12-01
Last updated by the study team
2016-03-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.